Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Case report of penpulimab, nab-paclitaxel, and anlotinib in porocarcinoma
Immunotherapy-Chemo Mix Shows Promise Against Stubborn Skin Cancer
This case report and literature review describes a 78-year-old female with porocarcinoma treated with penpulimab plus nab-paclitaxel, then a…
• A rare skin cancer slowed with immunotherapy plus chemo • Helps patients with porocarcinoma lacking treatment options • Still experimental
TQB2618 plus penpulimab shows 52% response in PD-1 refractory Hodgkin lymphoma
A New Drug Duo Revives Hope for Hodgkin Lymphoma After Immunotherapy Fails
A phase Ib single-arm trial in 21 Chinese patients with PD-1/PD-L1 inhibitor-refractory classic Hodgkin lymphoma found TQB2618 plus penpulim…
A new two-drug combination revived hope for Hodgkin lymphoma patients who failed prior immunotherapy, achieving a 52% response rate in early…
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…